We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK’s price watchdog is recommending reimbursement for AstraZeneca’s Tagrisso as a second-line treatment for an aggressive form of lung cancer. Read More
British drugmaker GlaxoSmithKline will pay $20 million to settle the U.S. Securities and Exchange Commission’s charges that the company bribed healthcare professionals to boost drug sales in China. Read More
The Indian government has revised its list of essential medicines, removing price caps on dozens of drugs in a number of therapeutic classes. Read More
The United Nations High-Level Panel on Access to Medicine is proposing that governments rely on compulsory licenses to improve patient access to medicines in a highly anticipated report that has been met with dismay from industry. Read More
A European Parliament committee is proposing that the European Commission promote transparency in private research to foster better access to medicines across the EU. Read More
The UK Court of Appeal affirmed an earlier ruling that invalidates Pfizer’s patent claims for Lyrica, saying generic versions will not lead to any infringement. Read More
The UK’s price watchdog is not recommending Janssen’s Imbruvica for the treatment of Waldenstrom's macroglobulinemia, a rare type of non-Hodgkin's lymphoma. Read More
Accessing a company’s policy on expanded access might be easier said than done, as most companies fail to post this information on their websites, a recent analysis found. Read More
The UK’s price watchdog is backing Celgene’s Otezla as a standalone or combined treatment for active psoriatic arthritis when other options are ineffective or not tolerated, provided the company discounts its price. Read More